Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERY-DEX versus placebo for steroid-dependent Crohn's disease
2008-007329-38Phase 3Terminated
- Sponsor
- EryDel S.p.A.
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone sodium phosphate in Crohn's disease (2 arms), sponsored by EryDel S.p.A. Primary endpoint: Maintenance of steroid-free clinical remission without surgery. Started Jan 2009; status: terminated.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-007329-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007329-38.